Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers
Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as bevacizumab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Combining
monoclonal antibody therapy with chemotherapy may be an effective treatment for hematologic
cancer.
PURPOSE: Phase II trial to study the effectiveness of bevacizumab combined with cytarabine
and mitoxantrone in treating patients who have hematologic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore
Collaborators:
National Cancer Institute (NCI) University of Maryland Greenebaum Cancer Center